News

One in 3,000 people at risk of punctured lung from faulty gene – almost 100 times higher than previous estimate

11 April 2025

Professor Stefan Marciniak and colleagues at the University of Cambridge has identified the link between the gene in question, FLCN, and a condition known as Birt-Hogg-Dubé syndrome, symptoms of which include benign skin tumours, lung cysts, and an increased risk of kidney cancer.

Combining antibiotics to tackle antimicrobial resistance

27 March 2025

William Hope (University of Liverpool), our professor Sharon Peacock and colleagues have published a new comment on Nature Microbiology, suggesting combining antibiotics remains a promising approach to treat patients and to prevent the emergence of antimicrobial resistance.

Maxion Therapeutics, co-founded by Dr John McCafferty, raises £58 million Series A financing

18 March 2025

Maxion Therapeutics, a Cambridge-based biotechnology company co-founded by Dr. John McCafferty, Associate Professor at CITIID and the Department of Medicine, University of Cambridge, has successfully raised $72 million in an oversubscribed Series A financing round. The company is developing antibody-based KnotBody® drugs...

When inflammation goes too far

13 March 2025

Clare Bryant takes a closer look at inflammation, and when our defence systems go too far.

Microbiome: ‘Good’ gut bacteria may protect against Salmonella infection

4 March 2025

New research from scientists at the University of Cambridge reveals how ‘good’ gut bacteria help protect against Salmonella, a major cause of food poisoning.

The Poppy team visit Addenbrooke’s Hospital in Cambridge

Carmel McEniery and the POPPY team are highly commended in the 2024 Cambridge Awards for Research Impact and Engagement

20 February 2025

We're delighted to announce that Dr Carmel McEniery, Principal Research Associate at the Department of Medicine, has been Highly Commended together with the POPPY team in the Established Academic Award of the Cambridge Awards 2024 for their exemplary work in raising awareness, fostering collaborations, and enriching research to improve women's health.

Prioritise vaccine boosters for vulnerable immunocompromised patients

13 February 2025

Vaccinations alone may not be enough to protect people with compromised immune systems from infection, even if the vaccine has generated the production of antibodies, new research from the University of Cambridge has shown.

New study shows how gut microbes affect cancer immunotherapy responses

12 February 2025

Lipopolysaccharide (LPS) produced in gut microbiota could influence how well cancer patients respond to immunotherapy treatments, as shown in a study published this week in Nature Microbiology .

Professor Duncan Richards appointed as Head of Department of Medicine

15 January 2025

Cambridge and GSK announce new five-year collaboration aiming for improved outcomes for patients with hard-to-treat kidney and respiratory diseases

15 January 2025

The Cambridge-GSK Translational Immunology Collaboration (CG-TIC) combines University and GSK expertise in the science of the immune system, AI and clinical development with access to patients and their data provided by Cambridge University Hospitals.

One in 3,000 people at risk of punctured lung from faulty gene – almost 100 times higher than previous estimate

Combining antibiotics to tackle antimicrobial resistance

Maxion Therapeutics, co-founded by Dr John McCafferty, raises £58 million Series A financing

When inflammation goes too far

Microbiome: ‘Good’ gut bacteria may protect against Salmonella infection

Carmel McEniery and the POPPY team are highly commended in the 2024 Cambridge Awards for Research Impact and Engagement

Prioritise vaccine boosters for vulnerable immunocompromised patients

New study shows how gut microbes affect cancer immunotherapy responses

Professor Duncan Richards appointed as Head of Department of Medicine

Cambridge and GSK announce new five-year collaboration aiming for improved outcomes for patients with hard-to-treat kidney and respiratory diseases

Our address

How we use information

Connect with us

Study at Cambridge

About the University

Research at Cambridge